ClinicalTrials.gov
public full text
Public Domain
Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)#865996
- Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)#842976
- Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer#1007917
- Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)#867149
- Sorafenib in Advanced Hepatocellular Carcinoma#6866
Record · ID 967194
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive